PSMA Antibody Fragments for Targeted Prostate Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as surgery, radiotherapy, and androgen deprivation therapy, have limited effectiveness for late-stage cancers, and there is a lack of PSMA-targeted antibodies for precision medicine.
Innovation Solution
Development of antibody fragments, such as scFv and full-length antibodies, that specifically bind to the extracellular domain of PSMA, enabling compositions like antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptors for targeted cancer treatment and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments (surgery, radiotherapy, chemotherapy, androgen deprivation therapy) are used for late-stage prostate cancer, then treatment options are available, but treatment effectiveness is limited
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by introducing PSMA-targeted antibody therapy, which targets a different molecular parameter (PSMA expression) compared to traditional treatments. This enables effective treatment of late-stage cancer by exploiting the high PSMA expression characteristic of aggressive prostate cancer cells
Solution Approach 2:
The patent uses PSMA as an intermediary target between the tumor and the therapeutic antibody. The PSMA protein serves as a mediator that allows the antibody to specifically recognize and bind to prostate cancer cells, enabling precise delivery of therapeutic effect to the tumor while sparing normal tissues
2Measurement precision
If PSMA-targeted antibody therapy is developed, then treatment precision is improved, but no PSMA antibodies are currently available on the market
Solution Approach 1:
The patent segments the antibody development process into distinct functional components: PSMA binding domain (for target recognition), Fc region (for effector functions), and linkage regions. This segmentation allows for modular design and optimization of different antibody components independently, facilitating the development of effective PSMA-targeted therapies
Solution Approach 2:
The patent employs computational modeling and in silico design to create virtual copies and variants of PSMA antibodies before physical production. This allows for extensive optimization of antibody sequences and structures through computer simulations, improving binding affinity and efficacy before actual manufacturing
3Reliability
If PSMA is used as a target marker, then tumor specificity is improved, but PSMA is also expressed in normal tissues (intestine, kidney, salivary gland)
Solution Approach 1:
The patent applies local quality by designing the antibody to recognize a specific local conformation or epitope on PSMA that is prevalent in tumor cells but rare or absent in normal tissues. The antibody's binding characteristics are optimized to differentiate between the tumor microenvironment and normal tissue expression patterns
Solution Approach 2:
The patent converts the presence of PSMA in normal tissues from a harmful factor into a beneficial one by exploiting the high PSMA expression in aggressive prostate cancer cells (which are often PSMA-positive) while the antibody's specificity ensures that normal tissue PSMA expression does not lead to significant off-target effects
4Reliability
If high PSMA expression is targeted, then cancer infiltration is reduced, but PSMA expression varies across different cancer stages and types
Solution Approach 1:
The patent designs a universal PSMA-targeting antibody that can recognize PSMA across different cancer stages and cell types. The antibody's binding site is selected to be conserved across various prostate cancer cell lines, enabling it to target PSMA-expressing tumors regardless of their specific characteristics or stage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions enhance the diagnosis and treatment of prostate cancer and other solid tumors by specifically targeting PSMA, improving treatment outcomes and reducing side effects through targeted toxicity delivery and immune cell activation.
Implementation Method 1
antibody or antibody fragment that specifically binds to the extracellular domain of PSMA
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to compositions and methods related to antibody or antibody fragments that specifically bind PSMA.